527 related articles for article (PubMed ID: 20041877)
1. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
2. The new European Medicines Agency guideline on the investigation of bioequivalence.
Morais JA; Lobato Mdo R
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):221-5. PubMed ID: 20070293
[TBL] [Abstract][Full Text] [Related]
3. United States Food and Drug Administration requirements for approval of generic drug products.
Meyer MC
J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
[TBL] [Abstract][Full Text] [Related]
4. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
5. Critical considerations into the new EMA guideline on bioequivalence.
Marzo A; Fontana E
Arzneimittelforschung; 2011; 61(4):207-20. PubMed ID: 21650079
[TBL] [Abstract][Full Text] [Related]
6. The bioequivalence of highly variable drugs and drug products.
Midha KK; Rawson MJ; Hubbard JW
Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
[TBL] [Abstract][Full Text] [Related]
7. Viewpoint: observations on scaled average bioequivalence.
Patterson SD; Jones B
Pharm Stat; 2012; 11(1):1-7. PubMed ID: 22162308
[TBL] [Abstract][Full Text] [Related]
8. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline.
Karalis V; Symillides M; Macheras P
Eur J Pharm Sci; 2011 Nov; 44(4):497-505. PubMed ID: 21945487
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
Marzo A; Balant LP
Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of the switchability of generic products.
Karalis V; Bialer M; Macheras P
Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
[TBL] [Abstract][Full Text] [Related]
11. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
Quiroz J; Ting N; Wei GC; Burdick RK
Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
[TBL] [Abstract][Full Text] [Related]
12. Current regulatory approaches of bioequivalence testing.
Karalis V; Macheras P
Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
[TBL] [Abstract][Full Text] [Related]
13. Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.
Spínola AC; Almeida S; Filipe A; Neves R; Trabelsi F; Farré A
Clin Ther; 2009 Sep; 31(9):1992-2001. PubMed ID: 19843489
[TBL] [Abstract][Full Text] [Related]
14. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
Bialer M; Midha KK
Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
[TBL] [Abstract][Full Text] [Related]
15. The subject-by-formulation interaction in multivariate bioequivalence.
Cao L; Mathew T
J Biopharm Stat; 2007; 17(3):367-79. PubMed ID: 17479387
[TBL] [Abstract][Full Text] [Related]
16. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.
García-Arieta A; Morales-Alcelay S; Herranz M; de la Torre-Alvarado JM; Blázquez-Pérez A; Suárez-Gea ML; Alvarez C
Int J Pharm; 2012 Feb; 423(2):321-5. PubMed ID: 22120644
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence review for drug interchangeability.
Chow SC; Shao J
J Biopharm Stat; 1999 Aug; 9(3):485-97. PubMed ID: 10473033
[TBL] [Abstract][Full Text] [Related]
18. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
Karalis V; Symillides M; Macheras P
Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
[TBL] [Abstract][Full Text] [Related]
20. Estimating product bioequivalence for highly variable veterinary drugs.
Claxton R; Cook J; Endrenyi L; Lucas A; Martinez MN; Sutton SC
J Vet Pharmacol Ther; 2012 Apr; 35 Suppl 1():11-6. PubMed ID: 22413787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
